Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Corteva Reaffirms Full Year 2024 Guidance; Net Sales Of $17.4B-$17.7B (Est $17.56B), Adj EPS Of $2.70-$2.90 (Est $2.83)

Author: Benzinga Newsdesk | May 01, 2024 05:14pm

 The Company plans to repurchase approximately $1.0 billion shares in 2024. Operating EBITDA1 is expected to be in the range of $3.5 billion to $3.7 billion, growth of 6% at the mid-point.

Posted In: CTVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist